Pfizer, Arvinas and Carrick Therapeutics collaborate for oncological combination

Carrick Therapeutics, an oncology-focused biopharmaceutical company, announced a clinical trial collaboration and supply agreement with Arvinas (ARVN) and Pfizer (PFE). This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib, an oral and first-in-class inhibitor of CDK7, and Arvinas’ vepdegestrant, an investigational oral Protac estrogen receptor protein degrader being developed in collaboration with Pfizer, in patients who have received prior CDK4/6i, with ER+, HER2- metastatic breast cancer. Arvinas will be the regulatory sponsor of the study in the U.S. and Pfizer will be the acting sponsor for the study conducted in the U.S., as well as the regulatory and acting sponsor of the study outside of the U.S. The three parties will collaborate through a Joint Development Committee. It is anticipated that the Phase 1b/2 trial will be initiated in the second half of 2023. Vepdegestrant is an investigational, orally-bioavailable Protac protein degrader designed to specifically target and degrade the estrogen receptor for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 negative breast cancer.